Dr. Gearóid Tuohy

Aldeyra Therapeutics Inc., (NASDAQ: ALDX) reports the launch of a Phase 2 study for methotrexate to treat Pro23His retinitis pigmentosa (RP)

Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), a clinical stage company based in Lexington, Massachusetts, has reported the initiation of a Phase 2 clinical trial of ADX-2191… Read More »Aldeyra Therapeutics Inc., (NASDAQ: ALDX) reports the launch of a Phase 2 study for methotrexate to treat Pro23His retinitis pigmentosa (RP)

X-linked Retinitis pigmentosa (XLRP) participants are invited to “My Retina Tracker Registry”, supported by Foundation Fighting Blindness

Foundation Fighting Blindness (FFB) are to invite a “Patient-Focused Drug Development” meeting, in the coming months, with Food and Drug Administration (FDA) representatives.  The objective… Read More »X-linked Retinitis pigmentosa (XLRP) participants are invited to “My Retina Tracker Registry”, supported by Foundation Fighting Blindness

ProQR Therapeutics N.V. (NASDAQ: PRQR), announces top-line results for the treatment of a novel RNA therapy (“Sepofarsen [QR-110]”) for LCA10

A Dutch biotechnology company, ProQR Therapeutcis N.V., (NASDAQ:PRQR), Leiden, has announced the results of a Phase 2/3 study for the treatment of Leber Congenital Amaurosis… Read More »ProQR Therapeutics N.V. (NASDAQ: PRQR), announces top-line results for the treatment of a novel RNA therapy (“Sepofarsen [QR-110]”) for LCA10

Next-generation sequencing data on inherited macular dystrophies (MD) shows significant impact among 1,036 Spanish families

Researchers at the Instituto de Investigación Sanitaria–Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid, has reported valuable clinical re-classifications from inherited dystrophies following next-generation… Read More »Next-generation sequencing data on inherited macular dystrophies (MD) shows significant impact among 1,036 Spanish families